Why Your Antidepressant Stopped Working (And What's Driving It)

Is the medication really losing effect, or is something else going on?

The question is harder than it looks. Same prescription, same dose, less benefit, and yet the cause can be one of several distinct structural mechanisms. The first job is diagnostic. A 2014 review by Steven Targum in Innovations in Clinical Neuroscience identifies four patterns that all present as "stopped working" but have different causes: pharmacological tolerance (true tachyphylaxis), breakthrough depression (a new clinical episode), inconsistent adherence (the dose is not actually being taken consistently), and discontinuation effects (withdrawal-pattern symptoms from intermittent dosing) [Targum, 2014, Innovations in Clinical Neuroscience].

The right next step is different in each case. Tolerance suggests a clinical conversation about changing the medication. Breakthrough depression suggests a conversation about life context. An adherence gap suggests a structural fix to the daily routine. Discontinuation effects suggest the dose is being missed often enough to trigger withdrawal between doses. Naming the four causes accurately is the first move.

What is antidepressant tachyphylaxis ("poop out")?

Antidepressant tachyphylaxis is the clinical term for true loss of medication effect over time, despite continued use at a stable dose. Patients often call it "poop out." The 2014 Targum review estimates prevalence at 9 to 33 percent of long-term users, with a best central estimate around 25 percent [Targum, 2014, Innovations in Clinical Neuroscience]. Maintenance trials show recurrence rates of 9 to 57 percent in people still taking medication, depending on population and follow-up length. Tachyphylaxis is real, and it is not a sign of personal failure.

It is also not the explanation for every felt loss of effect. True tachyphylaxis develops gradually over months to years on a stable, consistent dose; it does not usually appear over days or weeks. A sudden return of symptoms within a week more likely points at adherence or discontinuation.

A complicating finding from STAR*D, the largest United States trial of antidepressant treatment, is that initial remission rates were lower than many patients assume. The 2006 Trivedi and Rush analyses found that 28 percent of patients reached remission on first-line citalopram [Trivedi & Rush, 2006, American Journal of Psychiatry]. A treatment that was partially effective from the start can drift toward "not enough" over time without any pharmacological tolerance occurring at all. Whether your experience fits true tachyphylaxis or a different cause is a first conversation with your prescriber, not a decision to make alone.

How often is inconsistent dosing actually the cause?

More often than most readers expect. Two large reviews put adherence to long-term antidepressant treatment at roughly 50 percent by six months [Sansone & Sansone, 2012, Innovations in Clinical Neuroscience]. The same review tracked SSRI and SNRI adherence quarterly: 41 percent at 3 months, 31 percent at 6 months, 24 percent at 9 months, and 21 percent at 12 months. By the end of year one, fewer than one in four people are taking their medication as prescribed. The World Health Organization's 2003 report puts the depression-specific figure between 40 and 70 percent across chronic conditions, with depression at the lower end [World Health Organization, 2003, Adherence to Long-Term Therapies].

Depression itself increases the risk of nonadherence. A meta-analysis in the Journal of General Internal Medicine found depressed patients had 1.76 times the odds of nonadherence compared to non-depressed patients [Grenard et al., 2011, Journal of General Internal Medicine]. The condition the medication treats also makes the medication harder to take consistently.

The most common cause of a felt loss of effect is not that the medication failed; it is that the medication was not in the bloodstream consistently enough to maintain effect. A 2006 two-year primary-care study by Akerblad and colleagues found patients who maintained adherence had remission rates 11 to 22 percentage points higher than those who did not [Akerblad et al., 2006, International Clinical Psychopharmacology]. If you have been on a stable dose for more than 12 weeks and feel the medication has stopped working, the first diagnostic question is what your real-world adherence pattern looks like. That conversation is for your prescriber, not a self-adjustment decision.

What's the difference between tachyphylaxis, breakthrough depression, missed doses, and discontinuation effects?

Four causes can present as "stopped working," and each implies a different next step. Tachyphylaxis is the gradual loss of effect over months to years on a stable dose. Breakthrough depression is a new depressive episode that emerges despite the medication continuing to work pharmacologically; life context, biology, or a new stressor has shifted. An adherence gap is a pattern of inconsistent dosing where the bloodstream level cannot stabilize. Discontinuation effects are physiological symptoms (often "brain zaps," dizziness, flu-like sensations, or mood swings) that arise within days of a missed dose, especially on short-half-life medications.

The four overlap in lived experience but separate cleanly on cause. The table below maps each to the type of conversation it points toward.

The right diagnostic conversation is with your prescriber. Specific examples and time markers help: when the change started, what was happening around that time, and what the daily dosing pattern actually looked like.

What is discontinuation syndrome, and how does it mimic "stopped working"?

Discontinuation syndrome is the set of physiological and psychological symptoms that arise when antidepressant levels in the bloodstream drop too quickly. The 2013 Renoir review puts the overall rate at about 27 percent of patients on SSRIs, with steep variation by medication half-life: paroxetine carries an 85 percent rate, while fluoxetine, which has the longest half-life of the SSRIs, carries about 15 percent [Renoir, 2013, Frontiers in Pharmacology]. A 2006 American Family Physician review puts the overall rate at roughly 20 percent following abrupt discontinuation [Warner et al., 2006, American Family Physician].

Short-half-life medications make missed doses harder to hide. The Renoir review notes that SNRIs like venlafaxine and SSRIs like paroxetine can produce withdrawal-pattern symptoms within 24 hours of a single skipped dose. A reader who feels their medication "stopped working" within a day or two of an interrupted dose is more likely experiencing a discontinuation effect than a treatment failure.

Discontinuation effects can include returning low mood, anxiety, irritability, and flu-like malaise. These can look identical to the original depression resurging, but the timing is the diagnostic clue: discontinuation effects appear within days of a missed dose, while relapse typically takes weeks. The 2017 Goodwin survey also notes that 46 percent of patients on SSRIs report emotional blunting, which can be confused with both [Goodwin et al., 2017, Journal of Affective Disorders]. Do not change your dose on your own to test these distinctions. Any dose change is a prescriber decision.

When should you talk to your prescriber?

The short answer: before any change. The longer answer depends on which cause appears most likely. If you have been on the same dose for more than 12 weeks and feel the medication has stopped working over months, the conversation is about whether true tachyphylaxis is in play. If the loss of effect arrived suddenly within days, the conversation is about whether your dosing has been consistent and whether discontinuation symptoms are mimicking relapse. If you have been adherent and the loss of effect arrived over weeks, the conversation is about breakthrough depression and life context.

In every case, self-adjustment is the wrong first move. Stopping, skipping, doubling, or switching medications without clinical input introduces new structural problems. The right conversation includes specific examples (what changed, when), a clear timeline (how long this has been going on), and an honest account of adherence. If your prescriber is hard to reach in the short term, a pharmacist can answer specific questions about half-life and missed-dose handling as a first point of contact.

Where does Pause Moment fit?

Of the four causes covered above, only one is directly addressable by adherence architecture: the adherence-gap version. Pause Moment is not a treatment for tachyphylaxis, breakthrough depression, or discontinuation syndrome. It is one structural tool for the subset of cases where the felt loss of effect is driven by inconsistent daily dosing.

Pause Moment locks your screen instead of buzzing for attention — because the dismiss reflex is faster than willpower.

The mechanic is simple. Open Pause Moment. Pick the moment your dose should anchor to: morning routine, a meal, before bed. Set the lock duration: 1, 2, 3, 5, or 10 minutes. Choose a photo. Write the words you want yourself to read in that moment.

At the scheduled time, the phone shows your photo and your words and one button: "I'm Ready." Tap it. The screen locks. Notifications keep arriving but you cannot see them. The lock holds for the duration you chose. When the timer ends, the lock stays in place until you choose "I did it" or "I skipped this time."

This is structural friction, not willpower training. The decision happens once, when you are thinking clearly. If your felt loss of effect is driven by something other than adherence, a reminder structure will not fix it. That is honest scope.

Related from Pause Moment

• The Antidepressant Reminder for People Who Want to Take Their Meds and Keep Forgetting

  The full sub-pillar with the cluster B wedge framing and the consequence-led argument for medication adherence on SSRIs and SNRIs.

• Why You Keep Forgetting Your Antidepressant

  The architectural-causes article for the more general "I keep forgetting" experience. Companion piece to the discontinuation-effect content above.

• The Antidepressant Routine That Actually Sticks

  The how-to article for building a daily routine that holds across months. The structural fix to the adherence-gap version of "stopped working."

Frequently asked

Sources

1. Sansone RA & Sansone LA, 2012. Antidepressant adherence: are patients taking their medications? Innovations in Clinical Neuroscience 9(5-6):41-46. ncbi.nlm.nih.gov/pmc
2. World Health Organization, 2003. Adherence to Long-Term Therapies: Evidence for Action. iris.who.int
3. Grenard JL et al., 2011. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. Journal of General Internal Medicine 26(10):1175-1182. pubmed.ncbi.nlm.nih.gov
4. Akerblad AC et al., 2006. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. International Clinical Psychopharmacology 21(2):117-124. pubmed.ncbi.nlm.nih.gov
5. Targum SD, 2014. Identifying and treating antidepressant tachyphylaxis. Innovations in Clinical Neuroscience 11(3-4):24-28. pmc.ncbi.nlm.nih.gov
6. Renoir T, 2013. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome. Frontiers in Pharmacology 4:45. frontiersin.org
7. Warner CH et al., 2006. Antidepressant discontinuation syndrome. American Family Physician 74(3):449-456. aafp.org
8. Goodwin GM et al., 2017. Emotional blunting with antidepressant treatments: a survey among depressed patients. Journal of Affective Disorders 221:31-35. pubmed.ncbi.nlm.nih.gov
9. Trivedi MH, Rush AJ et al., 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D. American Journal of Psychiatry 163(1):28-40. pubmed.ncbi.nlm.nih.gov